Squamous Cell Lung Carcinoma — What It Is, in Plain Language

Squamous cell lung carcinoma is a type of lung cancer that starts in the flat, scale-like squamous cells that line the airways of the lungs. It is one of the two main forms of non-small cell lung cancer, alongside adenocarcinoma. You may also see it called squamous lung cancer, SCC lung, or epidermoid carcinoma of the lung — these are different names for the same thing. What sets it apart is that it usually begins more centrally, near the larger airways, which influences both the symptoms it causes and how it is treated. Knowing the exact type matters, because it helps your team plan care that fits your specific cancer rather than a one-size-fits-all approach.

Both are forms of non-small cell lung cancer, but they differ in where they start and how they behave. Squamous cell carcinoma usually begins in the central airways and has historically been more strongly linked with a smoking history. Adenocarcinoma is the most common type overall, tends to start in the outer parts of the lung, and is the type most often seen in people who have never smoked. Adenocarcinoma is also more likely to carry specific gene changes that can be targeted with certain medicines. Because the two types can respond differently to treatment, confirming which one you have through a biopsy is an important step before any plan is made.

Because squamous cell carcinoma often grows near the central airways, its symptoms frequently involve the breathing passages. Common signs include a cough that does not go away, coughing up blood, chest pain that is worse with breathing or coughing, and shortness of breath during everyday activities. Some people have recurrent chest infections that are slow to clear, a hoarse or changed voice, or unexplained tiredness and weight loss. None of these prove cancer on their own — many have far more common causes. But any symptom that persists beyond about three weeks, and any amount of coughing up blood, should be checked by a doctor without delay.

Yes. Squamous cell carcinoma is one of the main subtypes of non-small cell lung cancer (NSCLC), which is the larger group that makes up most lung cancers. The other common NSCLC subtypes are adenocarcinoma and large cell carcinoma. NSCLC is grouped separately from small cell lung cancer, which grows faster and is treated along a different path. Knowing that your cancer is squamous cell NSCLC helps your team decide which treatments are likely to help, because management often follows the broader NSCLC approach while still being tailored to the squamous type and your biomarker results.

Diagnosis usually moves through several steps. A CT scan of the chest gives a detailed picture of any abnormal area and nearby lymph nodes. Because squamous tumours often sit centrally, a bronchoscopy — a thin camera passed into the airways — is frequently used to look and take samples. A biopsy then confirms whether it is cancer and that it is the squamous cell type; this is the only test that can confirm the type for certain. The tissue is also checked with PD-L1 and molecular tests that help guide treatment, and a PET-CT scan stages how far the cancer has spread. Not everyone needs every test — the path is chosen based on what each result shows.

Squamous cell lung carcinoma has historically been strongly associated with a long history of smoking, including exposure to tobacco smoke over many years. Other risk factors recognised for lung cancer in general include exposure to secondhand smoke, radon gas, asbestos, and certain workplace chemicals, as well as long-term air pollution. Having a risk factor does not mean a person will develop the disease, and not everyone who develops it has an obvious cause. If you are worried about your own risk or symptoms, the most useful step is a calm conversation with a specialist who can look at your individual history and advise on what, if anything, needs checking.

Treatment depends on the stage of the cancer, your overall health, and the biomarker results from the biopsy. For earlier-stage cancer that has not spread, surgery to remove the affected part of the lung may offer the best chance of cure. Radiation therapy can be used on its own or combined with chemotherapy. For more advanced cancer, chemotherapy, immunotherapy, or a combination is often used, with immunotherapy guided by PD-L1 testing. At CION, every plan is agreed by a tumour board of medical, surgical, and radiation oncologists rather than one doctor alone, so the approach reflects the full team and is matched to your specific cancer.

Biomarker testing looks at specific proteins and gene changes in the biopsy tissue, and PD-L1 is one of the markers checked. These results help your team decide whether treatments such as immunotherapy are likely to help, and how best to combine treatments. Because squamous and non-squamous lung cancers can respond differently, this testing helps make treatment more personalised rather than one-size-fits-all. It is a routine part of working up a modern lung cancer diagnosis. Your doctor will explain which tests are relevant in your situation and what the results mean for your options, so the plan is built around your individual cancer.